诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

交易中 03-18 14:04:31 EDT

37.45

-0.98

-2.55%

最高37.69	最低37.00	成交量1,722万
今开37.46	昨收38.43	日振幅1.80%
总市值1,662亿	流通市值1,194亿	总股本44.39亿
成交额6.42亿	换手率0.54%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":37.45,"timestamp":1773857066563,"preClose":38.43,"halted":0,"volume":17215354,"delay":0,"changeRate":-0.025500910746812305,"floatShares":3187922885,"shares":4439052849,"eps":3.620568,"marketStatus":"交易中","change":-0.98,"latestTime":"03-18 14:04:31 EDT","open":37.455,"high":37.69,"low":37,"amount":642362184.86882,"amplitude":0.017955,"askPrice":37.45,"askSize":899,"bidPrice":37.44,"bidSize":229,"shortable":3,"etf":0,"ttmEps":3.620568,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":38.43,"dividendRate":0.04598,"preHourTrading":{"tag":"盘前","latestPrice":37.44,"preClose":38.43,"latestTime":"09:29 EDT","volume":2531947,"amount":95293481.476468,"timestamp":1773840599330,"change":-0.99,"changeRate":-0.025761,"amplitude":0.029404},"postHourTrading":{"tag":"盘后","latestPrice":38.4701,"preClose":38.43,"latestTime":"19:59 EDT","volume":257162,"amount":9890437.409,"timestamp":1773791983627,"change":0.0401,"changeRate":0.001043,"amplitude":0.004424},"volumeRatio":1.862069,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1778817600000,"strike":"35.0","timestamp":1773851481095,"price":2.01,"volume":2700,"amount":542700,"type":"-"},{"symbol":"NVO","call":true,"expireDate":1781755200000,"strike":"45.0","timestamp":1773843392341,"price":1.05,"volume":2000,"amount":210000,"type":"+"}]},"impliedVol":0.5314,"impliedVolPercentile":0.5896},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","IE00BKVL7J92.USD","AZN","IE00BFMHRM44.USD","NVOH","LU0757428866.USD","NVOX","LU0128526141.USD","BK4532","BK4530","BK4121","BK4007","LU0390134368.USD","LU1815336091.USD","REGN","IE00BZ1G4Q59.USD","BK4585","LU1093756168.USD","LU0154236417.USD","INCY","LU0029874061.USD","BK4599","NVO","LU1093756325.SGD"],"gpt_icon":0},{"id":"2618963769","title":"诺和诺德旗下“问题”工厂，又一家药企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618963769?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","NVOX","LU1093756168.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU0154236417.USD","NVO","BK4532","BK4588","BK4585","BK4599","BK4007","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2618895342","title":"Hims & Hers与诺和诺德达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618895342?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","HIMS","BK4585","LU1093756325.SGD","LU1093756168.USD","NVOX","LU0154236417.USD","BK4599","BK4532","NVOH","NVO"],"gpt_icon":0},{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672446?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4196","BK4585","LU1093756325.SGD","HIMY","IE00BKVL7J92.USD","HMYY","BK4532","NVOH","IE00BZ1G4Q59.USD","NVOX","BK4599","HIMS","BK4588","LU0154236417.USD","HIYY","NVO","LU1093756168.USD","HIMZ"],"gpt_icon":1},{"id":"2618781516","title":"诺和诺德盘中异动 股价大涨3.00%报39.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618781516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618781516?lang=zh_cn&edition=full","pubTime":"2026-03-10 00:15","pubTimestamp":1773072908,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日00时15分，诺和诺德股票出现异动，股价急速拉升3.00%。截至发稿，该股报39.74美元/股，成交量1310.03万股，换手率0.29%，振幅3.21%。诺和诺德股票所在的制药行业中，整体跌幅为0.48%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BKVL7J92.USD","NVO","LU1093756168.USD","BK4599","BK4585","BK4532","LU1093756325.SGD","BK4588","NVOH","IE00BZ1G4Q59.USD","NVOX","LU0154236417.USD"],"gpt_icon":1},{"id":"1127863922","title":"诺和诺德与Hims & Hers达成协议，后者将销售Wegovy和Ozempic并撤销诉讼，股价延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1127863922","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127863922?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:39","pubTimestamp":1773059964,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.  股价延续上涨态势，此前该公司与丹麦制药巨头诺和诺德达成合作协议，获得销售减肥药Wegovy和糖尿病药物Ozempic的授权。与此同时，诺和诺德已同意撤销对Hims & Hers提起的相关法律诉讼。分析人士指出，此次合作不仅解决了双方的法律纠纷，更为Hims & Hers打开了高达千亿美元的减肥药物市场大门。随着诺和诺德旗下明星产品Wegovy和Ozempic的加入，Hims & Hers的健康服务生态系统将得到进一步完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HIMY","HIMS","HMYY","BK4196","HIMZ","NVO"],"gpt_icon":0},{"id":"2618356626","title":"诺和诺德确认将在HIMS & HERS平台上销售WEGOVY、OZEMPIC产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618356626?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BK4532","BK4196","BK4599","NVOH","HIMS","BK4585","NVO","IE00BZ1G4Q59.USD","LU1093756325.SGD","HIYY","LU1093756168.USD","HIMZ","BK4588","HIMY","IE00BKVL7J92.USD","LU0154236417.USD","NVOX","HMYY"],"gpt_icon":0},{"id":"1146520715","title":"诺和诺德与Hims & Hers达成协议 美国消费者可自费获取Ozempic注射剂与Wegovy口服/注射制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1146520715","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146520715?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059474,"startTime":"0","endTime":"0","summary":"根据最新合作协议，丹麦制药巨头诺和诺德与美国远程医疗平台Hims & Hers Health Inc.将共同为美国消费者开启新型减重疗法通道。消费者可通过自费方式获得诺和诺德旗下三款明星产品：Ozempic注射剂、Wegovy口服片剂及Wegovy注射剂。而Ozempic注射剂与Wegovy注射剂作为经过市场验证的成熟产品，将共同构成完整的体重管理解决方案。对于正在寻找替代传统分销渠道的诺和诺德而言，与Hims & Hers的合作或将开创代谢疾病管理的新范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","NVO","HIMS","HIMY","BK4196","HIMZ","HIYY"],"gpt_icon":1},{"id":"1123143091","title":"诺和诺德：撤回对Hims & Hers的专利侵权诉讼，但保留未来重新起诉权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1123143091","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123143091?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059467,"startTime":"0","endTime":"0","summary":"诺和诺德(Novo Nordisk)已正式撤回对数字健康平台Hims & Hers Health Inc.提起的专利侵权诉讼。不过，这家丹麦制药巨头同时明确表示，其保留在未来针对相同事由再次提起诉讼的权利。\n此次诉讼的撤回标志着双方现阶段法律交锋的暂告段落，但诺和诺德此举也为其后续可能采取的法律行动预留了空间。市场分析认为，这反映了诺和诺德在保护其核心产品知识产权方面的持续决心与灵活策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIYY","HIMY","HIMZ","HMYY","NVO","HIMS"],"gpt_icon":0},{"id":"1174808259","title":"诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1174808259","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174808259?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059466,"startTime":"0","endTime":"0","summary":"诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","BK4196","HIMY","HIMZ","HMYY","HIMS","NVO"],"gpt_icon":0},{"id":"1176409964","title":"Hims & Hers Health盘后暴涨，诺和诺德计划在其平台上销售减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=1176409964","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176409964?lang=zh_cn&edition=full","pubTime":"2026-03-07 09:12","pubTimestamp":1772845960,"startTime":"0","endTime":"0","summary":"终结两家公司之间一场复杂的商业纠纷。","market":"us","thumbnail":"https://static.tigerbbs.com/f53bf305c44ae509dff85f95b455dca6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f53bf305c44ae509dff85f95b455dca6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Hims & Hers Health盘后暴涨，诺和诺德计划在其平台上销售减肥药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","HIMS"],"gpt_icon":0},{"id":"1157405095","title":"Hims & Hers Health盘后股价飙升39%，因报道称礼来与诺和诺德将合作销售减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=1157405095","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157405095?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:58","pubTimestamp":1772845133,"startTime":"0","endTime":"0","summary":"受到一则关于制药巨头将联手销售减肥药物的报道提振，Hims & Hers Health Inc.的股价在盘后交易时段录得惊人涨幅，飙升幅度高达39%。\n市场消息称，礼来公司与诺和诺德计划在肥胖症治疗药物领域展开合作，共同进行市场推广与销售。这一重磅合作传闻立即在投资者中引发强烈反响，显示出市场对减肥药市场巨大潜力的高度认可。\n作为一家专注于提供远程医疗服务和个性化健康解决方案的公司，Hims & Hers Health Inc.被市场视为减肥药物需求增长的重要受益者。投资者预期，行业领军企业的强强联合将进一步扩大市场规模，从而为Hims & Hers等相关企业带来显著的业务增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIYY","HMYY","HIMZ","BK4196","HIMS","NVO"],"gpt_icon":0},{"id":"2617656092","title":"Hims & Hers Health美股盘后涨近37%，报道称诺和诺德计划在Hims的平台上销售其减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617656092","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617656092?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:48","pubTimestamp":1772844525,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4550","TWM","LU0154236417.USD","NVOH","SRTY","BK4599","IE00BKVL7J92.USD","BK4007","UWM","LU1093756325.SGD","BK4535","LU1093756168.USD","HIMS","IWO","IE00BZ1G4Q59.USD","TNA","BK4532","RWM","BK4585","BK4588","BK4581","NVOX","TZA","IWN","MNQmain","NVO","BK4534"],"gpt_icon":0},{"id":"2617262656","title":"诺和诺德和HIMS将共同销售减肥药，结束双方的争端。","url":"https://stock-news.laohu8.com/highlight/detail?id=2617262656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617262656?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:34","pubTimestamp":1772843680,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO","HIYY","NVOX","NVOH","BK4532","BK4599","HIMY","BK4007","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4196","HIMZ","BK4585","LU0154236417.USD","LU1093756168.USD","HMYY","LU1093756325.SGD","HIMS"],"gpt_icon":0},{"id":"2617463761","title":"速递｜一针一周的组合拳：IcoSema在华获批，诺和诺德把胰岛素和GLP-1装进同一支笔","url":"https://stock-news.laohu8.com/highlight/detail?id=2617463761","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617463761?lang=zh_cn&edition=full","pubTime":"2026-03-06 23:24","pubTimestamp":1772810690,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队3月6日，国家药监局官网信息显示，诺和诺德的依柯胰岛素司美格鲁肽注射液 IcoSema 在中国获批上市，用于2型糖尿病治疗。IcoSema由两种活性成分组成。两者在中国此前都已分别获批上市，如今用复方形式打包，意味着诺和诺德把周制剂胰岛素的便利性与GLP-1的代谢收益，直接做成一条更省事的治疗路径。IcoSema的商业逻辑就在这里：把加用胰岛素和加用GLP-1这两步，尽量合并成一步，减少决策成本和执行成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603070219219543bc6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603070219219543bc6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","BK4590","NVO","BK4599","LU1093756325.SGD","LU1093756168.USD","NVOH","BK4585","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4532","BK4144"],"gpt_icon":1},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LU1066051498.USD","IE00BLSP4452.SGD","LU2097828714.EUR","MRK","000963","LU2097828474.EUR","PFE","SG9999001176.SGD","BK4534","LU1883839398.USD","SG9999001176.USD","LU2097828631.EUR","IE00B19Z3581.USD","LLY","LU0306806265.USD","LU0455707207.USD","LU0985481810.HKD","LU2242644610.SGD","BK4568","LU0058720904.USD","BK1161","NVO","LU0122379950.USD","LU0502904849.HKD","LU0225284248.USD","BK4585","SGXZ57979304.SGD","BK1589","SG9999013999.USD","LU0868494617.USD","SG9999002224.SGD","IE0002270589.USD","LU0321505868.SGD","LU2488822045.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","BK4592","LU2328871848.SGD","IE00BBT3K403.USD","01801","VKTX","LU1894683264.USD","LU1066053197.SGD","LU2097828805.USD","LU1023059063.AUD","HK0000165453.HKD","BK4599","AZN","BK1583","LU0234572021.USD","LU0306807586.USD","SG9999003800.SGD","LU0456855351.SGD","LU0170899867.USD","RHHBY","BK4581","IE00BLSP4239.USD","LU0321505439.SGD","SG9999011175.SGD","LU1057294990.SGD","BK4588","LU2097828557.USD","LU0225771236.USD","LU1969619763.USD","BK4550","SG9999002232.USD","LU1894683348.USD","BK4533"],"gpt_icon":1},{"id":"2617831166","title":"今日，诺和诺德 GLP-1 联合制剂国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617831166","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617831166?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:50","pubTimestamp":1772783431,"startTime":"0","endTime":"0","summary":"3 月 6 日，NMPA 官网显示，诺和诺德“依柯胰岛素+司美格鲁肽-IcoSema”在国内获批上市。根据公开信息和临床试验进展，Insight 数据库推断本次获批的适应症为用于在饮食和运动的基础上，接受基础胰岛素或 GLP-1 受体激动剂治疗控制不佳的成人 2 型糖尿病患者的治疗。2025 年 11 月，该药获欧洲药品管理局批准上市，用于治疗成人 2 型糖尿病，成为全球首个基础胰岛素 GLP-1RA 周制剂。胰岛素剂量方面，相较于依柯胰岛素组，IcoSema 组胰岛素剂量显著减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161755a6aa2ba6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161755a6aa2ba6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","BK4588","IE00BKVL7J92.USD","LU0154236417.USD","BK4144","NVOX","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4007","BK4599","BK4585","BK4590"],"gpt_icon":1},{"id":"2617577411","title":"诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评，即将惠及国内广大MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577411","media":"药研途","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577411?lang=zh_cn&edition=full","pubTime":"2026-03-06 07:28","pubTimestamp":1772753310,"startTime":"0","endTime":"0","summary":"2026年3 月 3 日，CDE 官网显示，诺和诺德“司美格鲁肽注射液”新适应症在国内申报上市，并拟纳入优先审评，适应症为：用于治疗代谢相关脂肪性肝炎伴中重度肝纤维化的非肝硬化成人患者。全球约有2.5亿MASH患者，其中超过三分之一的超重或肥胖人群同时患有MASH，疾病负担日益加重。司美格鲁肽治疗MASH的作用机制司美格鲁肽通过多重直接与间接途径改善MASH病理进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4599","BK4588","BK4532","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4007","NVO","LU1093756325.SGD","NVOX","IE00BZ1G4Q59.USD","NVOH"],"gpt_icon":1},{"id":"2617254074","title":"礼来瞄准雇主GLP-1覆盖 以与诺和诺德竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254074","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617254074?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:39","pubTimestamp":1772717940,"startTime":"0","endTime":"0","summary":"礼来公司推出“Employer Connect”，为新型多剂量Zepbound提供每月449美元的净价格，并与Teladoc Health和GoodRx等合作伙伴整合，以扩大肥胖药物的可及性；诺和诺德仍是主要竞争对手。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-05/doc-inhpycce3059268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0109394709.USD","LU1061106388.HKD","BK4590","LU0466842654.USD","LU0820561909.HKD","LU1712237335.SGD","LU1323610961.USD","BK4534","LU2750360997.AUD","IE0004445015.USD","BK4581","LU0640476718.USD","SGXZ57979304.SGD","IE00BFSS7M15.SGD","LLYZ","GB00BDT5M118.USD","LU2063271972.USD","LU0471298694.HKD","SG9999001176.USD","BK4007","LU1804176565.USD","SG9999015978.USD","LU0097036916.USD","LU2491050154.USD","LU0820562030.AUD","SGXZ81514606.USD","LU0158827948.USD","IE0004445239.USD","LU0323591593.USD","SG9999015986.USD","LU2265009873.SGD","LU0689472784.USD","IE0005OL40V9.USD","LU1868836591.USD","LU1868836757.USD","LU0094547139.USD","LU2213496289.HKD","LU2237438978.USD","LU2089283258.USD","LU0320765059.SGD","LU2552382058.USD","LU1720051108.HKD","LU2361044949.HKD","LU1127390331.HKD","LU2602419157.SGD","LU2271345857.HKD","SG9999014914.USD","LU0353189763.USD","LU2552382132.HKD","LU0385154629.USD","LU0203202063.USD","LU1983299246.USD","LU2417539215.USD","LU2237443549.SGD","IE00B1BXHZ80.USD","LU1989771016.USD","LU1069344957.HKD","LU0882574055.USD","LU0432979614.USD","IE00BFSS8Q28.SGD","LU1291159041.SGD","LU2468319806.SGD","IE00BK4W5M84.HKD","SG9999018857.SGD","SG9999017495.SGD","LU1064131342.USD","LU2168563687.JPY","LU0943347566.SGD","IE00BN29S564.USD","LU0786609619.USD","LU2456880835.USD","LU0823434583.USD","LU2750360641.GBP","BK4533","LU0417517546.SGD","LU2089284900.SGD","NVOH","LU1093756325.SGD","LU0079474960.USD","LU0353189680.USD","LU0471298777.SGD","LU0354030438.USD","LU1232071149.USD","LU0061475181.USD","IE00B4R5TH58.HKD","LU1551013425.SGD","LU2552382215.SGD","LU2360106947.USD","SG9999018865.SGD","ELIS","LU0820561818.USD","LU0316494557.USD","LU2237443622.USD","IE0001KFT4U8.USD","LU2746668974.SGD","BK4585","LU2756315318.SGD","LU0106261372.USD","LU1280957306.USD","LU0354030511.USD","LLY","IE00BJLML261.HKD","LU0096364046.USD","LLYX","LU1720051017.SGD","LU2264538146.SGD","ELIL","LU0210536198.USD","SG9999014898.SGD","LU1974910355.USD","LU2471134523.USD","LU2491049909.HKD","LU2357305700.SGD","LU0238689110.USD","LU0256863902.USD","LU1551013342.USD","LU0672654240.SGD","LU2237443382.USD","LU1366192091.USD","SGXZ31699556.SGD","BK4516","LU2471134879.HKD","LU2023250504.SGD","IE00BK4W5L77.USD","IE00BFTCPJ56.SGD","LU2168564222.USD","LU2237443465.HKD","LU0154236417.USD","IE00BJJMRZ35.SGD","LU2087625088.SGD","LU2236285917.USD","IE0009355771.USD","SG9999015952.SGD","LU2237443895.HKD","LU2106854487.HKD","LU1145028129.USD","LU2028103732.USD","LU1868837300.USD","LU2023250330.USD","LU0122379950.USD","LU2471134796.USD","LU2324357040.USD","LU0964807845.USD","IE00BJJMRY28.SGD","LU0456855351.SGD","NVOX","LU2361044865.SGD","SG9999001176.SGD","LU1057294990.SGD","LU2211815571.USD","IE00BKDWB100.SGD","BK4144","LU0198837287.USD","IE00BKPKM429.USD","LU0266013472.USD","LU1868836914.USD","LU2108987350.USD","LU2237443978.SGD","LU0058720904.USD","IE00B775H168.HKD","LU0256863811.USD","LU1035775433.USD","LU1548497426.USD","LU1917777945.USD","LU2023251221.USD","LU1023059063.AUD","LU2168564495.EUR","LU2111349929.HKD","LU0158827781.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BJJMRX11.SGD","LU0006306889.USD","LU1623119135.USD","LU2461242641.AUD","LU2491050071.SGD","LU0683600562.USD","IE00BZ1G4Q59.USD","LU2462157665.USD","LU1093756168.USD","IE0002141913.USD","BK4532","SGXZ99366536.SGD","LU1868837136.USD","IE00BJT1NW94.SGD","LU2471134952.CNY","LU1629891620.HKD","LU1814569148.SGD","BK4588","LU0708995401.HKD","LU2168564065.EUR","LU0787776722.HKD","SG9999013999.USD","LU0203201768.USD","IE00B2B36J28.USD","LU0289739699.SGD","BK4599","LU2361045086.USD","LU2746668461.USD","LU2089984988.USD","LU0882574139.USD","IE00BKVL7J92.USD","LU1267930730.SGD","SG9999015945.SGD","NVO","IE00B7KXQ091.USD","IE00B4JS1V06.HKD","SG9999014906.USD","IE00B1XK9C88.USD","LU0114720955.EUR","LU2112291526.USD","LU2756315664.SGD","SG9999014880.SGD","LU0823416689.USD","LU2168564149.EUR","SGXZ51526630.SGD","LU0109391861.USD","LLII","LU0234572021.USD","IE00BWXC8680.SGD","LU2896262040.SGD","LU1988902786.USD","LU0823434740.USD","LU0225283273.USD"],"gpt_icon":0},{"id":"2617959547","title":"诺和诺德、武田、默克等齐换帅，中国市场进入战略新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2617959547","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617959547?lang=zh_cn&edition=full","pubTime":"2026-03-05 09:53","pubTimestamp":1772675580,"startTime":"0","endTime":"0","summary":"2026年以来，诺和诺德、武田、默克等多家跨国药企相继完成中国区“换帅”。费森尤斯卡比中国宣布张巍3月2日加入，4月3日起任总裁兼董事长，她拥有超二十年医药行业经验；罗杰仁2月1日起任默克中国总裁，1月1日起兼任默克生命科学中国负责人，在医药健康和生命科学领域经验丰富；穆安德2月1日起任默克中国医药健康业务董事总经理，他是内部提拔晋升而来；诺和诺德中国宣布周霞萍3月31日离任，蔡琰同日接任大中国区总裁，周霞萍助力公司10款新药获批上市，蔡琰是资深管理者；1月底武田制药任命刘燕为武田中国总裁，负责整体战略和业务发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014567.USD","LU2361045086.USD","LU0868494617.USD","BK4588","KWEB","LU1162221912.USD","LU1116320901.HKD","LU0648001328.SGD","LU1699723380.USD","LU1917777945.USD","LU1116320737.USD","LU1571399168.USD","LU0265550359.USD","LU0477156953.USD","LU1066053197.SGD","LU0211331839.USD","LU0238689110.USD","LU1941712348.USD","LU0965508806.USD","LU0070302665.USD","LU0203347892.USD","SGXZ57979304.SGD","LU0130517989.USD","LU2468319806.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0985320562.USD","SG9999001176.USD","LU0234572021.USD","SG9999002232.USD","LU1066051811.HKD","LU1934455277.USD","NVOH","SG9999001176.SGD","BK4559","IE00BBT3K403.USD","LU1941712264.USD","IE00BLSP4452.SGD","BK4532","IE00B1BXHZ80.USD","LU2023250843.SGD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU1037948897.HKD","LU0106261372.USD","LU0203345920.USD","SG9999002224.SGD","LU0289739699.SGD","LU2112291526.USD","NVOX","LU1974910355.USD","LU2023250504.SGD","SG9999014575.USD","LU1057294990.SGD","BK4516","SG9999014542.SGD","LU0861579265.USD","LU0265550946.USD","LU1093756168.USD","IE00BSNM7G36.USD","IE000M9KFDE8.USD","LU0868494708.USD","LU0432979614.USD","BK4585","BK4504","LU0965509101.SGD","LU1061106388.HKD","BK4599","MRK","LU1934455194.USD","BK4533","CQQQ","LU2461242641.AUD","LU1929549753.HKD","LU0154236417.USD","LU2125154778.USD","ASHR","LU0965509010.AUD","DRAG","LU0006306889.USD","LU1066051225.USD","LU2125154935.USD","SG9999015358.SGD","SG9999014559.SGD","IE00B2B36J28.USD","LU2361044865.SGD","LU0942090050.USD","LU1430594728.SGD","NVO","LU0122379950.USD","TAK","LU1037948541.HKD","LU2361044949.HKD","LU1066051498.USD","LU0963586101.USD","LU0208291251.USD","LU1989771016.USD","SG9999013999.USD","LU1291159041.SGD","LU1035773651.USD","IE00BKVL7J92.USD","LU1983299246.USD","LU1093756325.SGD","LU2089984988.USD","BK4550","LU1069347547.HKD","LU2360032135.SGD","IE00BJT1NW94.SGD","SG9999015341.SGD","LU0965509283.SGD","LU1989772840.SGD","LU0130102774.USD","BK4614","LU1023059063.AUD","IE0009355771.USD","LU1989772923.USD","SG9999001440.SGD","ASHS","BK4534","MCHI","LU1201861249.SGD","LU0320765646.SGD","IE00BFTCPJ56.SGD","BK4007","LU1585245621.USD","LU2106854487.HKD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU1934455863.HKD","LU0266013472.USD","CWEB","IE0002141913.USD","LU0980610538.SGD","IE00B4R5TH58.HKD","LU0320765489.SGD","LU2324357040.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0075},{"period":"1month","weight":-0.2247},{"period":"3month","weight":-0.1955},{"period":"6month","weight":-0.3787},{"period":"1year","weight":-0.5205},{"period":"ytd","weight":-0.2447}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.466667,"avgChangeRate":0.007412},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}